Yoland C. Antill, MD, on Using a PARP Inhibitor in Maintenance Therapy for Ovarian Cancer

Posted: Sunday, June 2, 2019

What is your perspective on using a PARP inhibitor for maintenance therapy in ovarian cancer in a patient who has had a less-than-robust response to a previous platinum-containing regimen?